Streck Enters into Distribution Agreement with HiSS Diagnostics
By Labmedica International staff writers
Posted on 09 Feb 2017
Image: Streck has entered into a distribution agreement with HiSS Diagnostics (Photo courtesy of iStock).
Streck, Inc., which develops and manufactures products for clinical and research laboratories, has entered into a distribution agreement for its molecular and cell stabilization products with HiSS Diagnostics GmbH, a distributor of medical laboratory products.
Streck offers automated erythrocyte sedimentation rate instruments, kits and reagents, and blood collection tubes for sample collection, stabilization and transportation. Its product portfolio also includes flow cytometry, body fluids and urinalysis instruments, as well as molecular diagnostic instruments and consumables.
Streck’s cell stabilization products include Cell-Free DNA Urine Preserve, a formaldehyde-free liquid reagent that stabilizes cell-free DNA (cfDNA) in urine; Cell-Free DNA BCT CE, a direct-draw blood collection tube which stabilizes nucleated blood cells and prevents the release of genomic DNA, allowing isolation of high-quality cell-free DNA for a wide range of downstream applications commonly used in clinical research studies, drug discovery and diagnostic assay development; and Cell-Free RNA BCT CE, a blood collection tube with a patented preservative which stabilizes circulating RNA in plasma and prevents the release of non-target background RNA from blood cells during sample processing and storage. The company’s molecular product line includes Streck Antibiotic Resistance Monitoring & Detection (ARM-D) kits, PhilisaFAST DNA Polymerase and Streck’s Real-Time PCR System, the Zulu RT.
HiSS Diagnostics sells products for medical microbiology, immunology and quality assurance in the medical laboratory. Its product offerings also include a full range of antibodies for flow cytometry and hematology, research and diagnostics products for next-generation sequencing, microarrays and qPCR in oncology and hematology and other applications, isolation and sequencing of cell-free DNA in liquid biopsy.
“We are pleased to partner with a company that will allow Streck increased market penetration,” said Connie Ryan, President and CEO at Streck. “In addition, HiSS will be able to provide excellent local support to our German customers.”